Health-related quality of life in high-grade glioma patients: a prospective single-center study
Menée en Turquie auprès de 118 participants, cette étude analyse la qualité de vie et la détresse cognitive et émotionnelle de patients atteints d'un gliome de haut grade
Purpose In this single center study, we aimed to assess quality of life and cognitive and emotional distress in patients treated for high-grade glioma. Methods and materials A hundred and eighteen patients with high-grade glioma were prospectively enrolled. We assessed HRQoL at baseline (after surgery before radiotherapy), at the end of radiotherapy and during follow-up (every 3 months for the first 2 years and every 6 months between 2 and 5 years) using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC-C30), Brain Cancer Module-20 (BN-20), Minimental State Examination (MMSE) and Hospital Anxiety and Depression Scale (HADS). Baseline scores, and first 18-month follow-up period scores were included to statistical analysis. Results Sixty-five (55%) patients had progressive tumor. Global score, physical, role and emotional function, insomnia ( p for each <0.001) and appetite loss ( p : 0.008) scores of EORTC-C30 significantly related to disease progression. According to BN-20 seizure and leg weakness ( p < 0.001), drowsiness and bladder control ( p : 0.002), motor dysfunction ( p : 0.001), future uncertainty ( p : 0.04), visual disorder ( p : 0.008) and communication deficit ( p : 0.006) symptoms significantly related to disease progression. There were significant decrements in orientation, attention and calculation and language scores ( p values were 0.017, 0.005 and 0.003, respectively) of MMSE. The baseline and follow-up anxiety and depression scores did not differ significantly. Conclusion We conclude that there were many changes in patients with high-grade glioma during the course of the disease and most of them were related to disease progression.